Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON 2 25 versus QUIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON 2 25 versus QUIDE.
ETRAFON 2-25 vs QUIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of perphenazine (a typical antipsychotic) and amitriptyline (a tricyclic antidepressant). Perphenazine blocks postsynaptic dopamine D2 receptors in the mesolimbic system, also antagonizes alpha-adrenergic, histaminergic, and muscarinic receptors. Amitriptyline inhibits reuptake of serotonin and norepinephrine at the presynaptic neuronal membrane, enhancing serotonergic and noradrenergic neurotransmission.
Quetiapine acts as an antagonist at multiple neurotransmitter receptors in the brain, including serotonin 5-HT2A, dopamine D2, histamine H1, and adrenergic α1 receptors. It also has partial agonist activity at serotonin 5-HT1A receptors. This atypical antipsychotic action is mediated primarily through 5-HT2A and D2 antagonism.
One tablet (2 mg perphenazine, 25 mg amitriptyline) orally three or four times daily. Maintenance: 2-4 tablets daily.
5 mg orally once daily, with or without food.
None Documented
None Documented
Perphenazine: 8-12 hours (terminal); amitriptyline: 15-24 hours (terminal), with nortriptyline active metabolite half-life 18-44 hours. Steady-state achieved in 4-7 days.
2-4 hours (prolonged in renal impairment, requiring dose adjustment)
Renal: approximately 25-50% as metabolites and unchanged drug; biliary/fecal: 10-25% as metabolites; the remainder is extensively metabolized via hepatic pathways.
Primarily renal (80% as unchanged drug); minor fecal (20%)
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic